A new study that examined health data on 18 million people reveals higher incidence of mental illnesses for up to a year following severe COVID-19 in unvaccinated people.
The annual influenza vaccination provides updated protection against the virus but could be improved as there is large variability in its efficacy.
A unique influenza vaccine candidate that’s inhaled and based on technology developed by University of Wisconsin–Madison researchers is safe and could bolster protection against seasonal and pandemic influenza for people vulnerable to severe disease when they receive it in addition to the annual flu shot.Those are the results of a randomized, controlled trial of the vaccine candidate, administered in nasal spray form in conjunction with the annual shot to a group of 65- to 85-year-olds in 2022.
People with multiple sclerosis (MS) have an increased risk of severe coronavirus infection, but there has been concern regarding potential relapse after vaccination. A new study finds that people with MS may not have a higher risk of relapse after COVID-19 vaccination. The study is published in the August 14, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
School is right around the corner. Are you and your child ready for the new year? A Penn State Health expert offers a rundown of everything you need to keep your child healthy for 2024-2025.
Newirth beat the odds thanks to a novel cancer vaccine developed by UCLA neurosurgeon Linda Liau, MD, PhD. And now, he’s doing everything in his power to support cutting-edge cancer research and provide extra support to individuals going through cancer treatment.
Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.
In an effort to combat one of the most lethal forms of pediatric brain cancer, researchers at the UCLA Health Jonsson Comprehensive Cancer Center are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine targeting H3 G34-mutant diffuse hemispheric glioma, a highly aggressive brain tumor that is typically found in adolescents and young adults.
A nasal COVID-19 vaccine blocks transmission of the virus, according to an animal study by researchers at Washington University School of Medicine in St. Louis. The findings suggest that vaccines delivered directly to the nose or mouth could play a critical role in containing the spread of respiratory infections.
Researchers from University of California San Diego and el Colegio de la Frontera Norte in Mexico have revealed a link between illicit fentanyl use and the transmission of hepatitis C (HCV) among people who inject drugs in San Diego, California and Tijuana, Mexico.
A Cleveland Clinic-led study published in eBioMedicine reveals that maternal Zika virus infections can reprogram fetal immune development, leading to long-term consequences in children’s immunity.
A wave of COVID-19 over the summer is becoming as reliable as sizzling heat.
The risk of long COVID has declined over the course of the pandemic, although it remains a persistent threat. Researchers from Washington University School of Medicine in St. Louis identified vaccination as a primary factor in reducing the risk of long COVID.
HPV-related cancers disproportionately affect Hispanics, particularly those residing along the U.S.-Mexico border. Statistics reveal that cervical cancer incidence rates are notably higher in Texas-Mexico border counties: 12.3 per 100,000 people, compared to non-border counties, at 9.5 per 100,000.
July 16th at 6:30 pm EDT, Nobel Laureate in Medicine or Physiology Drew Weissman, M.D., Ph.D., delivers the 28th annual Jonathan Lax Memorial Lecture at The Wistar Institute in recognition of his outstanding contributions to HIV research.
MSU has a satellite uplink/LTN TV studio and Comrex line for radio interviews upon request.
In a study published today in the journal Clinical Infectious Diseases, a Johns Hopkins Medicine research team reports that for XBB.1.5, there is good news for solid organ transplant recipients (SOTRs) and other immunocompromised people who receive regular booster doses of a messenger RNA (mRNA) bivalent vaccine (a vaccine designed to enhance immunity to a variety of SARS-CoV-2 strains).
The first-ever global estimate of the economic costs of genital herpes infections shows billions of dollars of health care expenditures and productivity losses.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
